<DOC>
	<DOCNO>NCT00422240</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , parallel group study 12 week treatment acne vulgaris . Efficacy safety evaluation perform Screening ( safety ) , Baseline Weeks 1 , 2 , 4 , 8 12 . All Investigator 's Global Assessment evaluator lesion counter must train approve Galderma . The evaluator subject remain study . The primary objective demonstrate superiority efficacy assess safety adapalene/benzoyl peroxide topical gel ( adapalene/benzoyl peroxide gel ) versus adapalene topical gel , 0.1 % ( adapalene monad ) ; benzoyl peroxide topical gel , 2.5 % ( benzoyl peroxide monad ) topical gel vehicle ( gel vehicle ) treatment acne vulgaris 12 week .</brief_summary>
	<brief_title>Study Demonstrate Efficacy Safety Adapalene/Benzoyl Peroxide Topical Gel Subjects With Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Adapalene</mesh_term>
	<mesh_term>Adapalene , Benzoyl Peroxide Drug Combination</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>A clinical diagnosis acne vulgaris facial involvement . A minimum 20 50 inflammatory lesion A minimum 30 100 noninflammatory lesion A score 3 ( Moderate ) Investigator 's Global Assessment Scale</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Acne vulgaris</keyword>
	<keyword>Adapalene</keyword>
	<keyword>Benzoyl Peroxide</keyword>
</DOC>